Recent 8-K filings for TGTX

• August 3, 2026, 7:05 AM ET earnings materiality 0.80 positive item 2.02item 9.01

  TG Therapeutics Q2 2026 revenue $240M, raises FY2026 BRIUMVI guidance to ~$890-905M

  Q2 2026 total global revenue ~$240M; BRIUMVI U.S. net product revenue $227.7M, up 64% YoY.

• June 3, 2026, 7:34 AM ET other material materiality 0.75 positive item 8.01item 9.01

  TG Therapeutics reports positive Phase 1 data for subcutaneous BRIUMVI; bioavailability >60% vs IV

  Mean bioavailability >60% relative to IV; lower bound of 95% CI >55%.

• May 27, 2026, 4:34 PM ET other material materiality 0.90 positive item 8.01item 9.01

  TG Therapeutics announces positive Phase 3 ENHANCE trial results for BRIUMVI consolidated dosing

  Phase 3 ENHANCE trial met primary endpoint, demonstrating bioequivalent drug exposure between single 600 mg Day 1 infusion and approved 150 mg Day 1 + 450 mg Day 15 regimen.

• May 6, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  TG Therapeutics Q1 BRIUMVI US rev $194.8M; raises FY guidance to $885-900M

  Q1 2026 total global revenue approx $205M; BRIUMVI U.S. net product revenue $194.8M (+63% YoY).

• March 20, 2026, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings◈ Material Agreements

  TG Therapeutics establishes $750M term loan facility due 2031, repays prior term loans

  Borrowed $750M on March 18, 2026 under new term loan; proceeds used to fully repay initial term loans.

• February 26, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  TG Therapeutics Q4 BRIUMVI US revenue $182.7M (+20% QoQ); 2026 revenue guidance raised to $875-900M

  Q4 total revenue $192.6M; full year 2025 $616.3M; BRIUMVI US net revenue $594.1M (+92% YoY).

• January 13, 2026, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  TG Therapeutics prelim FY2025 global rev ~$616M; 2026 guided $875-900M

  Preliminary FY2025 total global revenue ~$616M; U.S. BRIUMVI net product rev Q4 ~$182M, FY ~$594M.

• November 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  TG Therapeutics raises BRIUMVI revenue guidance to $585M, Q3 net income $390.9M

  Q3 2025 total revenue $161.7M, BRIUMVI US net revenue $152.9M up 84% YoY.

• August 4, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  TG Therapeutics Q2 BRIUMVI revenue $138.8M (+91% YoY); raises FY guidance to $570-575M

  Q2 2025 total revenue $141.1M; BRIUMVI U.S. net sales $138.8M, up 91% YoY vs $72.6M.

• May 5, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  TG Therapeutics Q1 BRIUMVI sales $119.7M (+137% YoY); raises FY revenue guidance

  Q1 2025 BRIUMVI U.S. net revenue $119.7M vs $50.5M YoY, up ~137%.

• March 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  TG Therapeutics posts Q4 net income $23.3M; FY 2024 BRIUMVI revenue $310M, guides 2025 global rev ~$540M

  Q4 2024 BRIUMVI U.S. net revenue $103.6M; full year $310M, representing ~250% YoY growth.

• January 14, 2025, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  TG Therapeutics Prelim. Q4 BRIUMVI Rev $103.6M; FY2025 US Revenue Target $525M

  Preliminary Q4 2024 BRIUMVI U.S. net product revenue $103.6M; full year 2024 $310M.

• November 4, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  TG Therapeutics Q3 BRIUMVI revenue $83.3M, raises FY2024 guidance to $300-$305M

  BRIUMVI Q3 U.S. net sales $83.3M, up 15% QoQ and 230% YoY; full-year target raised to $300-$305M.

• August 6, 2024, 7:59 PM ET earnings materiality 0.85 positive item 1.01item 1.02item 2.2item 2.02item 8.01item 9.01

  TG Therapeutics Q2 BRIUMVI rev $72.6M, raises guidance; $250M credit facility; material weakness

  Q2 BRIUMVI net revenue $72.6M (+350% YoY); net income $6.9M vs loss $47.6M.

• June 17, 2024, 7:59 PM ET other material materiality 0.80 neutral item 5.02item 5.07item 5.03item 9.01

  TG Therapeutics shareholders approve share increase and incentive plan amendment at 2024 annual meeting

  Shareholders approved increasing authorized common stock from 175M to 190M (73.8M for, 36.3M against).

• May 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  TG Therapeutics Q1 BRIUMVI revenue $50.5M, raises FY guidance to $270-290M

  BRIUMVI U.S. net revenue $50.5M in Q1 2024, >25% QoQ growth; total revenue $63.5M includes $12.5M EU launch milestone.

• February 28, 2024, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  TG Therapeutics reports Q4 2023 BRIUMVI net revenue $39.9M; 2024 target $220-260M

  BRIUMVI U.S. net revenue $39.9M in Q4 2023, $88.8M for full year 2023.

• January 10, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  TG Therapeutics licenses azer-cel, reports preliminary Q4 BRIUMVI revenue $40M, FY2024 guidance $220-260M

  Upfront payment to Precision: $7.5M ($5.25M cash + $2.25M equity); deferred $2.5M equity; up to $288M milestone payments plus high-single-digit to low-double-digit royalties.

• November 1, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  TG Therapeutics Q3 total net revenue $165.8M; BRIUMVI net sales $25.1M, net income $113.9M

  BRIUMVI net sales $25.1M in Q3; ~$48.9M cumulative since launch; ~2,200 prescriptions from 500+ providers.

• August 1, 2023, 7:59 PM ET M&A materiality 0.85 positive item 1.01item 2.02item 9.01 ◈ Earnings Releases ×2◈ Material Agreements

  TG Therapeutics announces $645M ex-US BRIUMVI deal with Neuraxpharm; Q2 net sales $16M

  Upfront cash payment $140M plus $12.5M at first European launch; total deal up to $645M with milestones and double-digit royalties up to 30%.

• May 1, 2023, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  TG Therapeutics reports Q1 BRIUMVI net sales of $7.8M in first partial launch quarter

  BRIUMVI net sales $7.8M for Q1 2023; over 400 prescriptions from 165+ HCPs at 125+ centers.

• February 28, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  TG Therapeutics reports Q4 2022 net loss of $53M; launches BRIUMVI for RMS

  Net loss of $53.0M for Q4 2022, compared to $93.3M loss in Q4 2021; full year net loss $198.3M vs $348.1M.

• December 28, 2022, 6:59 PM ET regulatory materiality 0.90 positive item 8.01item 9.01

  FDA approves TG Therapeutics' BRIUMVI for relapsing multiple sclerosis; launch expected Q1 2023

  Approval based on ULTIMATE I & II Phase 3 trials showing annualized relapse rate reduction of 59% and 49% vs teriflunomide.

• November 10, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  TG Therapeutics reports Q3 net loss of $35.8M; ublituximab PDUFA set for Dec 28, 2022

  Net loss of $35.8M for Q3 2022 vs $85.6M in Q3 2021; nine-month net loss of $145.3M.

• August 8, 2022, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  TG Therapeutics Q2 net loss $40.5M, down from $78.5M YoY; cash $231.8M

  Net loss of $40.5M in Q2 2022 vs $78.5M in Q2 2021; six-month loss $109.5M vs $169.1M.

• April 18, 2022, 7:59 PM ET regulatory materiality 0.85 negative item 8.01item 9.01

  TG Therapeutics withdraws BLA/sNDA for U2 in CLL/SLL; pulls UKONIQ from sale

  Voluntarily withdrew BLA/sNDA for U2 (ublituximab + umbralisib) for CLL/SLL based on updated OS data imbalance favoring control arm.

• March 1, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  TG Therapeutics Q4 net loss $93.3M; UKONIQ revenue $2.3M; FDA partial hold on U2

  Net loss Q4 2021 $93.3M ($88.2M Q4 2020); full year net loss $348.1M ($279.4M 2020).

• January 27, 2022, 6:59 PM ET regulatory materiality 0.85 negative item 8.01item 9.01

  TG Therapeutics: updated UNITY-CLL OS data improves but FDA imposes partial clinical hold on U2 studies

  Updated OS hazard ratio improved vs preliminary 1.23; still not statistically significant (Sep 2021 cutoff).

• January 4, 2022, 6:59 PM ET debt materiality 0.65 neutral item 1.01item 9.01

  TG Therapeutics expands credit facility to $200M, extends maturity to 2026

  Loan increased from $60M to $200M; initial $70M drawn, $7.8M used to refinance existing balance.

• November 30, 2021, 6:59 PM ET regulatory materiality 0.75 negative item 8.01item 9.01

  FDA to hold ODAC meeting for TG Therapeutics' U2 BLA; PDUFA date likely extended

  FDA notified TG Therapeutics it will host an ODAC meeting for the U2 BLA/sNDA for CLL/SLL.

• November 4, 2021, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  TG Therapeutics Q3 net loss $85.6M; UKONIQ revenue $2.0M; ublituximab BLA for RMS submitted

  Net loss $85.6M Q3, $254.8M nine months; ex-stock comp net loss $71.6M and $207.8M.

• August 2, 2021, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  TG Therapeutics Q2 net loss $78.5M; UKONIQ revenue $1.5M; U2 PDUFA March 2022

  Net loss $78.5M for Q2 2021, up from $52.9M in Q2 2020; ex-stock comp net loss ~$62.2M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.78 · Most common event earnings

21 positive 8 negative 7 neutral

source · TGTX on sec.gov